科拓生物
(300858)
| 流通市值：29.17亿 | | | 总市值：40.55亿 |
| 流通股本：1.90亿 | | | 总股本：2.63亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 77,612,862.67 | 302,793,277.36 | 218,714,979.06 | 138,050,858.07 |
| 营业收入 | 77,612,862.67 | 302,793,277.36 | 218,714,979.06 | 138,050,858.07 |
| 二、营业总成本 | 56,526,026.1 | 211,440,159.85 | 152,721,092.56 | 96,896,107.04 |
| 营业成本 | 38,548,876.48 | 126,410,969.06 | 100,297,002.12 | 62,151,307.27 |
| 税金及附加 | 612,186.92 | 5,274,382.5 | 2,931,032.24 | 2,284,427.51 |
| 销售费用 | 7,268,846.55 | 36,507,476.96 | 24,751,458.36 | 15,925,717.01 |
| 管理费用 | 7,195,697.6 | 31,395,566.37 | 20,497,814.45 | 13,458,534.81 |
| 研发费用 | 7,884,151.19 | 36,327,014.28 | 24,045,152.14 | 16,056,661.13 |
| 财务费用 | -4,983,732.64 | -24,475,249.32 | -19,801,366.75 | -12,980,540.69 |
| 其中:利息费用 | 139,586.82 | 251,040.48 | 239,872.31 | 227,075.29 |
| 其中:利息收入 | 5,130,122.38 | 24,757,594.36 | 20,064,354.11 | 13,226,002.28 |
| 加:公允价值变动收益 | 316,957.27 | 2,013,454.04 | 1,486,574.28 | 1,282,054.8 |
| 加:投资收益 | 982,169.09 | 3,577,981.47 | 1,854,709.79 | 1,478,533 |
| 资产处置收益 | - | 652,262.64 | 566,011.33 | 566,011.33 |
| 信用减值损失(新) | 157,529.93 | 3,193,285.57 | 1,943,339.88 | 1,850,804.34 |
| 其他收益 | 2,789,709.85 | 8,672,581.21 | 7,938,974.89 | 3,802,616.83 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 25,333,202.71 | 109,462,682.44 | 79,783,496.67 | 50,134,771.33 |
| 加:营业外收入 | 23,011.47 | 58,229.03 | 76,067.77 | 44,793.12 |
| 减:营业外支出 | 0 | 692,974.62 | 176,598.86 | 102,058.85 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 25,356,214.18 | 108,827,936.85 | 79,682,965.58 | 50,077,505.6 |
| 减:所得税费用 | 5,026,589.55 | 14,471,856.39 | 8,492,040.88 | 6,562,520.14 |
| 六、净利润 | 20,329,624.63 | 94,356,080.46 | 71,190,924.7 | 43,514,985.46 |
| 持续经营净利润 | 20,329,624.63 | 94,356,080.46 | 71,190,924.7 | 43,514,985.46 |
| 归属于母公司股东的净利润 | 20,329,624.63 | 94,356,080.46 | 71,190,924.7 | 43,514,985.46 |
| (一)基本每股收益 | 0.08 | 0.36 | 0.27 | 0.17 |
| (二)稀释每股收益 | 0.08 | 0.36 | 0.27 | 0.17 |
| 八、其他综合收益 | -0.85 | 31.32 | - | - |
| 归属于母公司股东的其他综合收益 | -0.85 | 31.32 | - | - |
| 九、综合收益总额 | 20,329,623.78 | 94,356,111.78 | 71,190,924.7 | 43,514,985.46 |
| 归属于母公司股东的综合收益总额 | 20,329,623.78 | 94,356,111.78 | 71,190,924.7 | 43,514,985.46 |
| 公告日期 | 2025-04-23 | 2025-04-23 | 2024-10-30 | 2024-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |